1887

Abstract

Although much progress has been made in antiviral agents against hepatitis C virus (HCV) in recent years, novel HCV inhibitors with improved efficacy, optimized treatment duration and more affordable prices are still urgently needed. Here, we report the identification of a natural plant-derived lignan, trachelogenin (TGN), as a potent entry inhibitor of HCV without genotype specificity, and with low cytotoxicity. TGN was extracted and purified from Caulis trachelospermi, a traditional Chinese herb with anti-inflammatory and analgesic effects. A crucial function of TGN was the inhibition of HCV entry during a post-binding step without affecting virus replication, translation, assembly and release. TGN blocked virus infection by interfering with the normal interactions between HCV glycoprotein E2 and the host entry factor CD81, which are key processes for valid virus entry. In addition, TGN diminished HCV cell-to-cell spread and exhibited additional synergistic effects when combined with IFN or telaprevir. In conclusion, this study highlights the effect of a novel HCV entry inhibitor, TGN, which has a target that differs from those of the current antiviral agents. Therefore, TGN is a potential candidate for future cocktail therapies to treat HCV-infected patients.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000432
2016-05-01
2019-09-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/5/1134.html?itemId=/content/journal/jgv/10.1099/jgv.0.000432&mimeType=html&fmt=ahah

References

  1. Bankwitz D., Steinmann E., Bitzegeio J., Ciesek S., Friesland M., Herrmann E., Zeisel M. B., Baumert T. F., Keck Z. Y., other authors. ( 2010;). Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 84: 5751–5763 [CrossRef] [PubMed].
    [Google Scholar]
  2. Bartosch B., Dubuisson J., Cosset F. L.. ( 2003;). Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633–642 [CrossRef] [PubMed].
    [Google Scholar]
  3. Brimacombe C. L., Grove J., Meredith L. W., Hu K., Syder A. J., Flores M. V., Timpe J. M., Krieger S. E., Baumert T. F., other authors. ( 2011;). Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 85: 596–605 [CrossRef] [PubMed].
    [Google Scholar]
  4. Burlone M. E., Budkowska A.. ( 2009;). Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 90: 1055–1070 [CrossRef] [PubMed].
    [Google Scholar]
  5. Calland N., Albecka A., Belouzard S., Wychowski C., Duverlie G., Descamps V., Hober D., Dubuisson J., Rouillé Y., Séron K.. ( 2012;). ( − )-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55: 720–729 [CrossRef] [PubMed].
    [Google Scholar]
  6. Cox A. L.. ( 2015;). Global control of hepatitis C virus. Science 349: 790–791 [CrossRef] [PubMed].
    [Google Scholar]
  7. Crespo G., Mariño Z., Navasa M., Forns X.. ( 2012;). Viral hepatitis in liver transplantation. Gastroenterology 142: 1373–1383 [CrossRef] [PubMed].
    [Google Scholar]
  8. Drummer H. E., Wilson K. A., Poumbourios P.. ( 2002;). Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol 76: 11143–11147 [CrossRef] [PubMed].
    [Google Scholar]
  9. Dubuisson J., Hsu H. H., Cheung R. C., Greenberg H. B., Russell D. G., Rice C. M.. ( 1994;). Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68: 6147–6160 [PubMed].
    [Google Scholar]
  10. El-Fakharany E. M., Sánchez L., Al-Mehdar H. A., Redwan E. M.. ( 2013;). Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study. Virol J 10: 199 [CrossRef] [PubMed].
    [Google Scholar]
  11. Fang C. Y., Chen S. J., Wu H. N., Ping Y. H., Lin C. Y., Shiuan D., Chen C. L., Lee Y. R., Huang K. J.. ( 2015;). Honokiol, a lignan biphenol derived from the magnolia tree, inhibits dengue virus type 2 infection. Viruses 7: 4894–4910 [CrossRef] [PubMed].
    [Google Scholar]
  12. Gane E. J., Stedman C. A., Hyland R. H., Ding X., Svarovskaia E., Symonds W. T., Hindes R. G., Berrey M. M.. ( 2013;). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34–44 [CrossRef] [PubMed].
    [Google Scholar]
  13. Gnabre J. N., Brady J. N., Clanton D. J., Ito Y., Dittmer J., Bates R. B., Huang R. C.. ( 1995;). Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Proc Natl Acad Sci U S A 92: 11239–11243 [CrossRef] [PubMed].
    [Google Scholar]
  14. Guan M., Wang W., Liu X., Tong Y., Liu Y., Ren H., Zhu S., Dubuisson J., Baumert T. F., other authors. ( 2012;). Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem 287: 35631–35645 [CrossRef] [PubMed].
    [Google Scholar]
  15. Haid S., Novodomská A., Gentzsch J., Grethe C., Geuenich S., Bankwitz D., Chhatwal P., Jannack B., Hennebelle T., other authors. ( 2012;). A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology e5: 213–222 [CrossRef] [PubMed].
    [Google Scholar]
  16. Ji C., Liu Y., Pamulapati C., Bohini S., Fertig G., Schraeml M., Rubas W., Brandt M., Ries S., other authors. ( 2015;). Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody. Hepatology 61: 1136–1144 [CrossRef] [PubMed].
    [Google Scholar]
  17. Kohli A., Shaffer A., Sherman A., Kottilil S.. ( 2014;). Treatment of hepatitis C: a systematic review. JAMA 312: 631–640 [CrossRef] [PubMed].
    [Google Scholar]
  18. Law M., Maruyama T., Lewis J., Giang E., Tarr A. W., Stamataki Z., Gastaminza P., Chisari F. V., Jones I. M., other authors. ( 2008;). Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25–27 [CrossRef] [PubMed].
    [Google Scholar]
  19. Lawitz E., Sulkowski M. S., Ghalib R., Rodriguez-Torres M., Younossi Z. M., Corregidor A., DeJesus E., Pearlman B., Rabinovitz M., other authors. ( 2014;). Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384: 1756–1765 [CrossRef] [PubMed].
    [Google Scholar]
  20. Lee J., Huh M. S., Kim Y. C., Hattori M., Otake T.. ( 2010;). Lignan, sesquilignans and dilignans, novel HIV-1 protease and cytopathic effect inhibitors purified from the rhizomes of Saururus chinensis. Antiviral Res 85: 425–428 [CrossRef] [PubMed].
    [Google Scholar]
  21. Lee M. H., Lee J. M., Jun S. H., Ha C. G., Lee S. H., Kim N. W., Lee J. H., Ko N. Y., Mun S. H., other authors. ( 2007;). In-vitro and in-vivo anti-inflammatory action of the ethanol extract of Trachelospermi caulis. J Pharm Pharmacol 59: 123–130 [CrossRef] [PubMed].
    [Google Scholar]
  22. Liang T. J., Ghany M. G.. ( 2013;). Current and future therapies for hepatitis C virus infection. N Engl J Med 368: 1907–1917 [CrossRef] [PubMed].
    [Google Scholar]
  23. Lupberger J., Zeisel M. B., Xiao F., Thumann C., Fofana I., Zona L., Davis C., Mee C. J., Turek M., other authors. ( 2011;). EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17: 589–595 [CrossRef] [PubMed].
    [Google Scholar]
  24. Meuleman P., Hesselgesser J., Paulson M., Vanwolleghem T., Desombere I., Reiser H., Leroux-Roels G.. ( 2008;). Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48: 1761–1768 [CrossRef] [PubMed].
    [Google Scholar]
  25. Nahmias Y., Casali M., Barbe L., Berthiaume F., Yarmush M. L.. ( 2006;). Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology 43: 257–265 [CrossRef] [PubMed].
    [Google Scholar]
  26. Nishibe S., Han Y. M.. ( 2002;). Chemical constituents from Trachelospermum jasminoides and its anticancer activity. World Phytomed 17: 57–58.
    [Google Scholar]
  27. Pelosi L. A., Voss S., Liu M., Gao M., Lemm J. A.. ( 2012;). Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 56: 5230–5239 [CrossRef] [PubMed].
    [Google Scholar]
  28. Petracca R., Falugi F., Galli G., Norais N., Rosa D., Campagnoli S., Burgio V., Di Stasio E., Giardina B., other authors. ( 2000;). Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 74: 4824–4830 [CrossRef] [PubMed].
    [Google Scholar]
  29. Qin Z.-L., Ju H.-P., Gao T.-T., Wang W.-B., Ren H., Zhao P., Qi Z.-T.. ( 2015;). Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry. J Gen Virol 96: 1389–1399 [CrossRef] [PubMed].
    [Google Scholar]
  30. Redwan E. M., El-Fakharany E. M., Uversky V. N., Linjawi M. H.. ( 2014;). Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus. BMC Complement Altern Med 14: 219 [CrossRef] [PubMed].
    [Google Scholar]
  31. Seal A., Aykkal R., Babu R., Ghosh M.. ( 2011;). Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation 5: 430–439 [CrossRef] [PubMed].
    [Google Scholar]
  32. Sulkowski M. S., Kang M., Matining R., Wyles D., Johnson V. A., Morse G. D., Amorosa V., Bhattacharya D., Coughlin K., other authors. ( 2014;). Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209: 658–667 [CrossRef] [PubMed].
    [Google Scholar]
  33. Swarup V., Ghosh J., Mishra M. K., Basu A.. ( 2008;). Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother 61: 679–688 [CrossRef] [PubMed].
    [Google Scholar]
  34. Thomas D. L.. ( 2013;). Global control of hepatitis C: where challenge meets opportunity. Nat Med 19: 850–858 [CrossRef] [PubMed].
    [Google Scholar]
  35. Tong Y., Zhu Y., Xia X., Liu Y., Feng Y., Hua X., Chen Z., Ding H., Gao L., other authors. ( 2011;). Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol 85: 2793–2802 [CrossRef] [PubMed].
    [Google Scholar]
  36. Vausselin T., Calland N., Belouzard S., Descamps V., Douam F., Helle F., François C., Lavillette D., Duverlie G., other authors. ( 2013;). The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 58: 86–97 [CrossRef] [PubMed].
    [Google Scholar]
  37. Vieyres G., Thomas X., Descamps V., Duverlie G., Patel A. H., Dubuisson J.. ( 2010;). Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 84: 10159–10168 [CrossRef] [PubMed].
    [Google Scholar]
  38. Xiao W. L., Wang R. R., Zhao W., Tian R. R., Shang S. Z., Yang L. M., Yang J. H., Pu J. X., Zheng Y. T., Sun H. D.. ( 2010;). Anti-HIV-1 activity of lignans from the fruits of Schisandra rubriflora. Arch Pharm Res 33: 697–701 [CrossRef] [PubMed].
    [Google Scholar]
  39. Zhang Y. Y., Zhang B. H., Ishii K., Liang T. J.. ( 2010;). Novel function of CD81 in controlling hepatitis C virus replication. J Virol 84: 3396–3407 [CrossRef] [PubMed].
    [Google Scholar]
  40. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D. R., Wieland S. F., Uprichard S. L., Wakita T., Chisari F. V.. ( 2005;). Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294–9299 [CrossRef] [PubMed].
    [Google Scholar]
  41. Zhu Y. Z., Luo Y., Cao M. M., Liu Y., Liu X. Q., Wang W., Wu D. G., Guan M., Xu Q. Q., other authors. ( 2012;). Significance of palmitoylation of CD81 on its association with tetraspanin-enriched microdomains and mediating hepatitis C virus cell entry. Virology 429: 112–123 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000432
Loading
/content/journal/jgv/10.1099/jgv.0.000432
Loading

Data & Media loading...

Supplementary Data



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error